Study S000273

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise

ClinicalTrials.gov record

Registration

Registration: NCT06323174
Acronym: REIMAGINE 1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 189
Start: 2024-03-19
Primary completion: 2025-10-01
Lead sponsor: Novo Nordisk A/S
Conditions: Type 2 Diabetes
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:2022-502677-42; OTHER:U1111-1283-0404

Registered primary outcomes

Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 40)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004235	Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Aroda VR, The lancet. Diabetes & endocrinology	2026	Randomized trial	PMID 42251860 DOI	cites ClinicalTrials.gov:NCT06323174; registry reference DERIVED:42251860